These findings suggest that inhibition of FDFT1 and blocking the de novo cholesterol biosynthesis pathway may be an attractive therapeutic strategy to eliminate cancer stem cells and inhibit tumour cell growth. The gene discussed is FDFT1; the disease is cancer.